Press release
BRAF-mutant Non-Small Cell Lung Cancer Pipeline Drugs 2024 | Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics, Inc., and others.
BRAF-mutant Non-Small Cell Lung Cancer Pipeline
Explore our latest breakthroughs in BRAF-mutant Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ BRAF-mutant Non-Small Cell Lung Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the BRAF-mutant Non-Small Cell Lung Cancer Pipeline Report
• April 2024:- Pfizer- This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC). Patients who are either treatment-naïve, OR who have received 1) first-line treatment with standard platinum-based chemotherapy, OR 2) first-line treatment with an anti-programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) inhibitor given alone or in combination with platinum-based chemotherapy will be enrolled.
• April 2024:- Immuneering Corporation- A Phase 1/2a Study of IMM-6-415 in Participants With Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic Mutations. This is a FIH, ascending dose study to characterize the safety, tolerability, optimal dose and preliminary anti-tumor activity of IMM-6-415 in participants with advanced or metastatic solid tumors harboring RAS or RAF oncogenic mutations.
• DelveInsight's BRAF-mutant Non-Small Cell Lung Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for BRAF-mutant Non-Small Cell Lung Cancer treatment.
• The leading BRAF-mutant Non-Small Cell Lung Cancer Companies such as Pierre Fabre Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics, Inc., and others.
• Promising BRAF-mutant Non-Small Cell Lung Cancer Therapies such as IMM-6-415, binimetinib, encorafenib, Trametinib, Dabrafenib, and others.
Stay informed about the cutting-edge advancements in BRAF-mutant Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in oncology care @ BRAF-mutant Non-Small Cell Lung Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
BRAF-mutant Non-Small Cell Lung Cancer Emerging Drugs Profile
• Encorafenib/Binimetinib: Pierre Fabre Medicament
BRAFTOVI (encorafenib) is a BRAF kinase inhibitor, indicated in combination with MEKTOVI (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation. The combination is currently investigated in Metastatic BRAFV600-mutant Non-Small Cell Lung Cancer in Phase II trial with completion expected in March 2025. This combination is indicated and being tested for several other indications.
• XP-102: Xynomic Pharmaceuticals, Inc.
XP-102 is a second generation potent and selective pan-RAF inhibitor uniquely binding to the DFG-out conformation, whereas marketed BRAF inhibitors occupy the DFG-in conformation. XP-102 holds potential as an innovative therapy against B-RAF V600 mutated solid tumors including CRC and non-small cell lung cancer and hairy cell leukemia. The drug is currently being investigated for several tumor including non-small cell lung cancer in Phase I/II which is expected to be completed by December 2024.
Learn more about BRAF-mutant Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking BRAF-mutant Non-Small Cell Lung Cancer Research and development projects @ BRAF-mutant Non-Small Cell Lung Cancer Unmet Needs- https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
BRAF-mutant Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
BRAF-mutant Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Discover the latest advancements in BRAF-mutant Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ BRAF-mutant Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the BRAF-mutant Non-Small Cell Lung Cancer Pipeline Report
• Coverage- Global
• BRAF-mutant Non-Small Cell Lung Cancer Companies- Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics, Inc., and others.
• BRAF-mutant Non-Small Cell Lung Cancer Therapies- IMM-6-415, binimetinib, encorafenib, Trametinib, Dabrafenib, and others.
• BRAF-mutant Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• BRAF-mutant Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of BRAF-mutant Non-Small Cell Lung Cancer Pipeline on our website @ BRAF-mutant Non-Small Cell Lung Cancer Drugs and Companies- https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. BRAF-mutant Non-Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. BRAF-mutant Non-Small Cell Lung Cancer- DelveInsight's Analytical Perspective
7. Mid Stage Products (Phase II)
8. Encorafenib/Binimetinib: Pierre Fabre Medicament
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase I/II)
11. XP-102: Xynomic Pharmaceuticals, Inc.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. BRAF-mutant Non-Small Cell Lung Cancer Key Companies
21. BRAF-mutant Non-Small Cell Lung Cancer Key Products
22. BRAF-mutant Non-Small Cell Lung Cancer- Unmet Needs
23. BRAF-mutant Non-Small Cell Lung Cancer- Market Drivers and Barriers
24. BRAF-mutant Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
25. BRAF-mutant Non-Small Cell Lung Cancer Analyst Views
26. BRAF-mutant Non-Small Cell Lung Cancer Key Companies
27. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Yash Bhardwaj
info@delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release BRAF-mutant Non-Small Cell Lung Cancer Pipeline Drugs 2024 | Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics, Inc., and others. here
News-ID: 3607871 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for RAF
Interview released with RAF Programme Manager: Reaper and Protector ahead of SMi …
SMi reports: Exclusive insights released from RAF Programme Manager: Reaper and Protector ahead of upcoming UAV Technology conference in London
As the development of new UAS technology continues to advance, and procurement and acquisition increase at a fast pace, SMi will host its fourth annual UAV Technology conference, taking place on the 30th September – 1st October 2019, in London, UK.
Ahead of the two-day conference, SMi Group caught up with…
Senior RAF representative to present on Typhoon jet capabilities as Tornado reti …
SMi reports: Senior expert from the RAF will be discussing the recent advancements in Typhoon jets as they replace the retired Tornado at the Close Air Support Conference in London, this June.
In recent news, RAF Typhoons are all set to replace the retired Tornados in Operation ‘Shader’, as they carry the Brimstone 2 precision attack missile for the first time in January.
This means that the Typhoon can now transport…
Self Priming Pump Industry 2017 Market Research Report - Frank n Raf
As per Frank n Raf’s Research Report the Self-Priming Pumps market revenue was xx.xx Million USD in 2013, increased to xx.xx Million USD in 2017, and will touch xx.xx Million USD in 2023, with a CAGR of x.x% through the years 2018-2023. Based on the Self-Priming Pumps industrial chain, this report mainly elaborate on the definition, types, applications and major players of Self-Priming Pumps market in details. This report will…
Construction In The UAE Market – by Size, Growth, Opportunities and Key Trends …
Frank n Raf’s this Market research report provides Synopsis In real seasons, the UAE construction industry posted confident growth during the study period (20122016). Construction activity encountered a slight slowdown during 2015, owing to the collision of low oil prices. In addition, the economic slowdown in China measured the UAEs economic performance. Despite average economic growth, the countrys construction industry recorded positive growth during the review period, encouraged by the…
Argentina, South Africa, France, UK RAF and more look to upgrade their Military …
SMi Reports: Military Flight Training returns to London on 11th -12th October 2017 to maximise flight training capabilities for the 21st century’s aircraft.
Military flight training experts and world leading solution providers will meet at SMi Group’s 8th annual Military Flight Training taking place in London on 11th-12th October 2017.
Military Flight Training continues to be an essential aspect for Defence Forces and military air craft manufacturers worldwide.…
Workshop on UK MoD & RAF Agenda Released for Air Mission Planning and Support 20 …
Air Mission Planning and Support 2017 returns to London on 5-6 April 2017 and will feature a pre-conference workshop led by WhiteFlare Consulting.
The Conference will uncover how leading nations are delivering their most advanced air mission planning and support systems to date. Key subjects include:
• The F-35 Lighting II Joint Programme
• The optimization and development of the Gripen Fleet
• Delivering Effective Air Mission Planning and Support Strategies
• Improving interoperability between partner Air Forces
Attendees…
